Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence
DC immunotherapy is a safe treatment for transplant recipients with HCC recurrence. Adding DC-immunotherapy to the treatment regimen could prolong the survival of some patients.
Authors
- Tsung‐Han Wu (ORCID: https://orcid.org/0000-0002-5083-8851)
- Hao‐Chien Hung (ORCID: https://orcid.org/0000-0001-8830-3679)
- Hong‐Shiue Chou (ORCID: https://orcid.org/0000-0002-3583-2048)
- Jin‐Chiao Lee (ORCID: https://orcid.org/0000-0001-6075-8786)
- Ting-Jung Wu (ORCID: https://orcid.org/0000-0001-8911-8758)
- Chen‐Fang Lee (ORCID: https://orcid.org/0000-0001-6292-7694)
- Kun‐Ming Chan (ORCID: https://orcid.org/0000-0002-7566-0113)
- Yu-Chao Wang (ORCID: https://orcid.org/0000-0002-9236-5001)
- Wei‐Chen Lee (ORCID: https://orcid.org/0000-0002-8627-1324)
- Chih‐Hsien Cheng (ORCID: https://orcid.org/0000-0001-8176-0631)
Institutions
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1589634
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80